Press release:

Mitsubishi Tanabe Pharma Corporation

Notice Regarding Arbitration Award in Dispute with Janssen Biotech, Inc.

Osaka, Japan, August 8, 2013—Mitsubishi Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka, President and Representative Director: Michihiro Tsuchiya) announces that the Company has received an arbitration decision from the International Chamber of Commerce (ICC) in a dispute with Janssen Biotech, Inc. (formerly Centocor Ortho Biotech Inc., Head Office: Pennsylvania, U.S.). The dispute involved the supply price for Remicade 100mg IV Solution (generic name: infliximab), an anti-TNFα monoclonal antibody sold by the Company in Japan. In January 2009, the Company submitted the request for arbitration to the ICC requesting a revision in the supply price in accordance with the development and distribution agreement, and the arbitration decision awarded a reduction in the supply price.

Consequently, approximately $117 million was reimbursed to the Company as the overpayment attributable to previous years (from April 2008 to March 2013).

Remicade, a treatment agent for rheumatoid arthritis (RA) and other diseases, was discovered by Janssen Biotech. In 1993, the Company concluded the development and distribution agreement under which Mitsubishi Tanabe develops and sell Remicade in Japan and certain parts of Asia. In 2002, Remicade was launched in Japan as a treatment agent for Crohn’s disease.

The Company is scrutinizing the impact that the arbitration decision will have on the Company’s consolidated results forecast.

<Media enquiry>
Corporate Communications Department
Phone: +81 6-6205-5211